Intellia Therapeutics is a clinical-stage biotechnology company developing in vivo and ex vivo CRISPR/Cas9-based gene-editing therapies. Its lead program NTLA-2001 is being studied for transthyretin (ATTR) amyloidosis, with additional programs in hereditary angioedema, hemophilia A/B, and other genetic diseases. Intellia has also invested heavily in commercial-launch infrastructure, including a dedicated team working on cell-and-gene therapy readiness in advance of its first potential approvals.
Company Info
Upcoming Milestones & Key Dates
MAGNITUDE Phase 3 topline data in ATTR amyloidosis with cardiomyopathy
BLA submission readiness update for NTLA-2002 in HAE
Clinical Development Pipeline
Recent News
Intellia Therapeutics' SVP Maria Natale outlines the commercial launch playbook for gene-editing therapies, arguing the most successful launches are shaped long before approval with strategy, structure, and patient insight at the core.
Leadership Team
President and Chief Executive Officer
Senior Vice President, Commercial
Chief Medical Officer
Careers & Job Openings